US Covid-19: US FDA approves Pfizer's Paxlovid pill for at home treatment of Covid-19

Joel Frank Independent Analyst

The US Food and Drug Administration on Wednesday authorised Pfizer's Paxlovid pill, the first anti-Covid-19 treatment pill to be authorised in the country. It will be used to treat high-risk patients with moderate to severe disease within five days of symptom onset. Pfizer said it was ready to commence delivery of the pill immediately.

The latest news comes on the back of seperate positive pandemic developments. Namely, a recent study released by Scottish scientists showed Omicron infection to be associated with about a two-thirds reduced risk of hospitalisation, a conclusion in fitting with similar studies conducted in South Africa.

Market Reaction

Markets have switched from trading in a quite a subdued fashion earlier in the session to more of a risk on mode in recent trade, with stocks, crude oil and risk sensitive currencies all gaining in recent trade. The aforementioned positive pandemic newsflow is likely contributing to a sense of optimism that while Omicron is a threat to the global economy, it does not look set to deliver a lasting blow to growth, given its lesser severity, high vaccination rates in developed countries and the upcoming rollout of effective treatments.

Author

Joel Frank

Independent Analyst

Joel Frank is an economics graduate from the University of Birmingham and has worked as a full-time financial market analyst since 2018, specialising in the coverage of how developments in the global economy impact financial asset

Markets move fast. We move first.

Orange Juice Newsletter brings you expert driven insights - not headlines. Every day on your inbox.

Editor's Picks

EUR/USD drops to daily lows near 1.1630

EUR/USD now loses some traction and slips back to the area of daily lows around 1.1630 on the back of a mild bounce in the US Dollar. Fresh US data, including the September PCE inflation numbers and the latest read on December consumer sentiment, didn’t really move the needle, so the pair is still on course to finish the week with a respectable gain.

GBP/USD trims gains, recedes toward 1.3320

GBP/USD is struggling to keep its daily advance, coming under fresh pressure and retreating to the 1.3320 zone following a mild bullish attempt in the Greenback. Even though US consumer sentiment surprised to the upside, the US Dollar isn’t getting much love, as traders are far more interested in what the Fed will say next week.

Gold makes a U-turn, back to $4,200

Gold is now losing the grip and receding to the key $4,200 region per troy ounce following some signs of life in the Greenback and a marked bounce in US Treasury yields across the board. The positive outlook for the precious metal, however, remains underpinned by steady bets for extra easing by the Fed.